Potti Anil, Ganti Apar Kishor, Tendulkar Ketki, Chitajallu Sidharth, Sholes Kaley, Koch Michael, Kargas Steven
Department of Medicine, University of North Dakota School of Medicine, Fargo, ND 58102, USA.
Anticancer Res. 2003 May-Jun;23(3B):2671-4.
Hepatocellular carcinoma has an overall 5-year survival of less than 5%. Similarly, pancreatic cancer has a mortality: incidence ratio of 0.99. The aim of this study was to determine the prevalence of HER-2/neu and c-kit (CD117) overexpression and to identify a possible predictive role in patients with these two malignancies.
We performed a retrospective study on archival specimens of subjects with hepatocellular and pancreatic carcinoma. HER-2/neu and CD117 overexpression were evaluated by immunohistochemistry.
Thirty-three patients with pancreatic carcinoma and 25 patients with hepatocellular carcinoma were identified. The mean age was 71.7 years for patients with pancreatic carcinoma and 66 years for patients with hepatocellular carcinoma. Two patients with hepatocellular carcinoma and none with pancreatic cancer overexpressed HER-2/neu, while 2 patients with pancreatic carcinoma and 1 patient with hepatocellular carcinoma overexpressed CD117.
HER-2/neu and CD117 are not significantly overexpressed in either cancer. There appears to be no role for the use of trastuzumab in either malignancy. Similarly, while there appears to be no role for tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma, further larger studies are necessary in pancreatic adenocarcinoma.
肝细胞癌的总体5年生存率低于5%。同样，胰腺癌的死亡率与发病率之比为0.99。本研究的目的是确定HER-2/neu和c-kit（CD117）过表达的患病率，并确定其在这两种恶性肿瘤患者中的可能预测作用。
我们对肝细胞癌和胰腺癌患者的存档标本进行了回顾性研究。通过免疫组织化学评估HER-2/neu和CD117的过表达情况。
共纳入33例胰腺癌患者和25例肝细胞癌患者。胰腺癌患者的平均年龄为71.7岁，肝细胞癌患者的平均年龄为66岁。2例肝细胞癌患者HER-2/neu过表达，胰腺癌患者无HER-2/neu过表达；2例胰腺癌患者和1例肝细胞癌患者CD117过表达。
HER-2/neu和CD117在这两种癌症中均无明显过表达。曲妥珠单抗在这两种恶性肿瘤中似乎均无应用价值。同样，虽然酪氨酸激酶抑制剂在肝细胞癌治疗中似乎无应用价值，但在胰腺腺癌中还需要进一步开展更大规模的研究。
